欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子化合物 > 小分子抑制剂 > LCZ696

商品分类

浏览历史

S81127

LCZ696

MedMol 99%
  • 英文名:
  • LCZ696
  • 别名:
  • CAS号:
  • 936623-90-4
  • 分子式:
  • C48H60N6Na3O10.5
  • 分子量:
  • 957.99
品牌货号产品规格价格(RMB)库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
MedMol S81127-1mg 99% ¥170.00元 >10 0 0 0 EA 加入购物车
MedMol S81127-5mg 99% ¥297.50元 >10 0 0 0 EA 加入购物车
MedMol S81127-10mg 99% ¥510.00元 >10 0 0 0 EA 加入购物车
MedMol S81127-25mg 99% ¥850.00元 >10 0 0 0 EA 加入购物车
MedMol S81127-50mg 99% ¥1530.00元 >10 0 0 0 EA 加入购物车
MedMol S81127-100mg 99% ¥2720.00元 >10 0 0 0 EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献

质检证书(COA)

摩尔浓度计算器

相关产品

  • 提示:详情请下载说明书。
  • 产品描述: Sacubitril/Valsartan (LCZ696), comprised Valsartan and Sacubitril (AHU377) in 1:1 molar ratio, is a first-in-class, orally bioavailable, and dual-acting angiotensin receptor-neprilysin (ARN) inhibitor for hypertension and heart failure. Sacubitril/Valsartan ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis
  • 靶点: Angiotensin receptor-neprilysin
  • 体外研究: Sacubitril/Valsartan (LCZ696; 1-30 µM; 0.5 hours) inhibits HG-treated H9C2 cells apoptosis in an experimental model of Diabetic cardiomyopathy (DCM). Sacubitril/Valsartan (1-30 µM; 0.5 hours) increases the expression level of cleaved caspase-3 and the ratio of Bax/Bcl-2 in HG-treated H9C2 cells. Apoptosis Analysis Cell Line: HG-treated H9C2 cells Concentration: 1, 10, or 30 µM Incubation Time: 0.5 hours Result: Inhibited HG-treated H9C2 cells apoptosis. Western Blot Analysis Cell Line: HG-treated H9C2 cells Concentration: 1, 10, or 30 µM Incubation Time: 0.5 hours Result: Increased the expression level of cleaved caspase-3 and the ratio of Bax/Bcl-2.
  • 体内研究: Sacubitril/Valsartan (LCZ696; perorally; 68 mg/kg for 4 weeks) significantly exhibits small weights and reduces interstitial fibrosis both in the noninfarct zone and peri-infarct zone. Animal Model: Adult 6- to 8-week-old male Sprague-Dawley rats (220-250 g body weight) Dosage: 68 mg/kg Administration: Perorally; for 4 weeks Result: Exhibited small weights and reduced interstitial fibrosis both in the noninfarct zone and peri-infarct zone.
  • 参考文献:
    1. Gu J, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010 Apr;50(4):401-14. 2. von Lueder TG, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015 Jan;8(1):71-8. 3. Huo H, et al. Erastin Disrupts Mitochondrial Permeability Transition Pore (mPTP) and Induces Apoptotic Death of Colorectal Cancer Cells. PLoS One. 2016 May 12;11(5):e0154605. 4. Ge Q, et al. Feature article: LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabeticcardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis. Exp Biol Med (Maywood). 2019 Sep;244(12):1028-1039.
  • 溶解性: Soluble  in  DMSO、H2O
  • 保存条件: -20℃
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 1.044 ml 5.219 ml 10.439 ml
    5 mM 0.209 ml 1.044 ml 2.088 ml
    10 mM 0.104 ml 0.522 ml 1.044 ml
    50 mM 0.021 ml 0.104 ml 0.209 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。